dc.contributor.author | Dukinfield, M | en_US |
dc.contributor.author | Maniati, E | en_US |
dc.contributor.author | Reynolds, LE | en_US |
dc.contributor.author | Aubdool, A | en_US |
dc.contributor.author | Baliga, RS | en_US |
dc.contributor.author | D'Amico, G | en_US |
dc.contributor.author | Maiques, O | en_US |
dc.contributor.author | Wang, J | en_US |
dc.contributor.author | Jr, BKC | en_US |
dc.contributor.author | Margulies, KB | en_US |
dc.contributor.author | Sanz-Moreno, V | en_US |
dc.contributor.author | Hobbs, A | en_US |
dc.contributor.author | Hodivala-Dilke, K | en_US |
dc.date.accessioned | 2019-09-20T16:51:59Z | |
dc.date.available | 2019-08-15 | en_US |
dc.date.issued | 2019-12 | en_US |
dc.identifier.issn | 0022-3417 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/59784 | |
dc.description.sponsorship | British Heart Foundation (BHF) FS/14/66/31293 | en_US |
dc.description.sponsorship | Cancer Research UK (CRUK C8218/A18673 programme | en_US |
dc.description.sponsorship | BHF Programme Grant RG/16/7/32357 | en_US |
dc.description.sponsorship | CRUK-Barts Cancer Centre funds | en_US |
dc.description.sponsorship | National Heart Lung and Blood Institute of the United States National Institutes of Health (Grants HL089847 and HL105993 to KBM) | en_US |
dc.description.sponsorship | Cancer Research UK (C33043/A24478) | en_US |
dc.description.sponsorship | Barts Charity | en_US |
dc.format.extent | 523 - 535 | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | JOURNAL OF PATHOLOGY | en_US |
dc.rights | "This is the peer reviewed version of the following article: Dukinfield, M. , Maniati, E. , Reynolds, L. E., Aubdool, A. , Baliga, R. S., D'Amico, G. , Maiques, O. , Wang, J. , Bedi, K. C., Margulies, K. B., Sanz‐Moreno, V. , Hobbs, A. and Hodivala‐Dilke, K. (2019), Repurposing an anti‐cancer agent for the treatment of hypertrophic heart disease. J. Pathol.. Accepted Author Manuscript. doi:10.1002/path.5340 which has been published in final form at https://doi.org/10.1002/path.5340. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions." | |
dc.subject | heart failure | en_US |
dc.subject | blood vessels | en_US |
dc.subject | hypertrophy | en_US |
dc.subject | integrins | en_US |
dc.subject | angiogenesis | en_US |
dc.subject | cardiomyocyte | en_US |
dc.subject | ischaemia | en_US |
dc.subject | cilengitide | en_US |
dc.title | Repurposing an anti-cancer agent for the treatment of hypertrophic heart disease | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1002/path.5340 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493100900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 4 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 249 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |